Inflarx (NASDAQ:IFRX) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a note issued to investors on Tuesday.
According to Zacks, “InflaRx N.V. is a clinical-stage biopharmaceutical company. It focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. InflaRx N.V. is based in Germany. “
Other equities analysts also recently issued research reports about the company. SunTrust Banks initiated coverage on Inflarx in a research report on Thursday, June 28th. They issued a “buy” rating and a $55.00 price objective for the company. BMO Capital Markets assumed coverage on Inflarx in a research note on Friday, July 13th. They issued an “outperform” rating and a $45.00 target price for the company. Finally, Raymond James assumed coverage on Inflarx in a research note on Thursday, June 28th. They issued an “outperform” rating and a $44.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $42.67.
Shares of IFRX opened at $32.51 on Tuesday. Inflarx has a 52-week low of $14.47 and a 52-week high of $42.83. The firm has a market capitalization of $803.43 million and a price-to-earnings ratio of -11.06.
Inflarx (NASDAQ:IFRX) last issued its quarterly earnings data on Thursday, August 9th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.36) by $0.24. On average, equities research analysts expect that Inflarx will post -1.43 earnings per share for the current year.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in IFRX. Barclays PLC acquired a new stake in shares of Inflarx in the 1st quarter valued at $144,000. Northern Trust Corp acquired a new stake in shares of Inflarx in the 1st quarter valued at $228,000. Schwab Charles Investment Management Inc. acquired a new stake in shares of Inflarx in the 1st quarter valued at $367,000. Birchview Capital LP acquired a new stake in shares of Inflarx in the 2nd quarter valued at $516,000. Finally, Millennium Management LLC acquired a new stake in shares of Inflarx in the 2nd quarter valued at $1,916,000. 54.80% of the stock is owned by institutional investors.
Inflarx Company Profile
InflaRx N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing inhibitors using C5a technology primarily in the United States and Europe. Its C5a is an inflammatory mediator involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company’s lead product candidate is IFX-1, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that is in the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of other chronic/autoimmune diseases.
Featured Article: Understanding Analyst Ratings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Inflarx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Inflarx and related companies with MarketBeat.com’s FREE daily email newsletter.